<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492398</url>
  </required_header>
  <id_info>
    <org_study_id>HY209-202</org_study_id>
    <nct_id>NCT03492398</nct_id>
  </id_info>
  <brief_title>A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis</brief_title>
  <acronym>Shaperon</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Single Multiple Dosing, Dose Escalation Phase I Clinical Trial to Investigate HY209 Gel in Healthy Male Volunteers as a Possible Treatment Option for Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaperon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaperon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled single and multiple dosing, dose escalation&#xD;
      phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209&#xD;
      gel after transdermal administration in healthy male volunteers as a possible treatment&#xD;
      option for atopic dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A composition containing G Protein Coupled Receptor 19(GPCR19) agonist HY209 and a derivative&#xD;
      thereof is found to have a considerable effect in the treatment of atopic dermatitis and is&#xD;
      proposed as a pharmaceutical ingredient for prevention, treatment and improvement of atopic&#xD;
      dermatitis. The GPCR19 agonist, HY209, is superior to conventional steroid ointment and&#xD;
      immunosuppressant ointment in the treatment and improvement of allergic dermatitis. It&#xD;
      directly reduces the amount of serum immunoglobulin E, which is a major factor of allergic&#xD;
      dermatitis, It increases the T helper type 1(TH1) cytokines that alleviate allergic&#xD;
      dermatitis pathologies, reduces the T helper type 2(TH2) cytokines that aggravate allergic&#xD;
      dermatitis pathologies, and reduces the infiltration of mast cells, eosinophils and&#xD;
      neutrophils into the dermal cells. Thus it can be utilized as a therapeutic drug composition&#xD;
      for atopic dermatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Actual">May 28, 2019</completion_date>
  <primary_completion_date type="Actual">March 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double blind, placebo-controlled, single and multiple dosing, dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>upto Day 8(single dosing), upto Day 38(multiple dosing)</time_frame>
    <description>Number of participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort A HY209 0.05% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of HY209 0.05% gel or single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A HY209 0.1% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of HY209 0.1% gel or single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A HY209 0.3% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of HY209 0.3% gel or single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A HY209 0.5% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of HY209 0.5% gel or single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B HY209 0.1% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of HY209 0.1% gel or multiple dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B HY209 0.3% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of HY209 0.3% gel or multiple dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B HY209 0.5% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of HY209 0.5% gel or multiple dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HY209</intervention_name>
    <description>6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.</description>
    <arm_group_label>Cohort A HY209 0.05% gel</arm_group_label>
    <arm_group_label>Cohort A HY209 0.1% gel</arm_group_label>
    <arm_group_label>Cohort A HY209 0.3% gel</arm_group_label>
    <arm_group_label>Cohort A HY209 0.5% gel</arm_group_label>
    <arm_group_label>Cohort B HY209 0.1% gel</arm_group_label>
    <arm_group_label>Cohort B HY209 0.3% gel</arm_group_label>
    <arm_group_label>Cohort B HY209 0.5% gel</arm_group_label>
    <other_name>HY209 gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male aged from 20 to 50 at screening test&#xD;
&#xD;
          -  Weight 45kg ~ 90kg with BMI 17kg/m2 ~ 27kg/m2&#xD;
&#xD;
          -  No skin diseases, no skin damages(scars, tattoo, etc), no hairy skin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have a history of hypersensitivity or clinically significant&#xD;
             hypersensitivity reactions to generic drugs (aspirin, antibiotics, etc.)&#xD;
&#xD;
          -  Those who have clinically significant liver, kidney, respiratory, endocrine,&#xD;
             neurologic diseases or hematologic diseases, mental diseases, especially hemorrhagic&#xD;
             diseases (hemophilia, von Willebrand disease, etc.), cardiovascular diseases (coronary&#xD;
             artery disease, Congestive heart failure, arrhythmia, cerebrovascular disease, etc.)&#xD;
             or who have a history of those diseases&#xD;
&#xD;
          -  Those who had clinical symptoms suspected of acute infectious disease within 2 weeks&#xD;
             before the scheduled date of the first administration, or whose temperature measured&#xD;
             by the screening test (eardrum) was 38.0 Â° C or higher&#xD;
&#xD;
          -  Those who have taken any prescription drugs, herbal medicines, crude drugs within 2&#xD;
             weeks before the scheduled date of administration of the medicines for clinical trials&#xD;
             , or over-the-counter medicines or vitamin preparations within 1 week.&#xD;
&#xD;
          -  Those who have a history of substance abuse, or positive urine screening tests&#xD;
             (cannabinoid, opiates, amphetamine, cocaine, barbiturate, benzodiazepine)&#xD;
&#xD;
          -  Those who have a history of smoking within 3 months (However, if they quit smoking&#xD;
             three months before the first scheduled medication, they are eligible for selection)&#xD;
&#xD;
          -  Those who have been found to be positive in serological tests (HBs antigen, hepatitis&#xD;
             C virus antibody and HIV antibody)&#xD;
&#xD;
          -  Those who drink continuously (above 21 units / week, 1 unit = 10 g of pure alcohol)&#xD;
&#xD;
          -  Those who have been taking medicines by participating in other clinical trials or&#xD;
             bioequivalence studies within 3 months prior to the date of first dosing&#xD;
&#xD;
          -  Those who have been bleeding, blood drawings or blood donation of 400mL or more within&#xD;
             8 weeks before the scheduled date of administration of the drug for clinical trials&#xD;
&#xD;
          -  Those who have vital signs measured at sitting position after the break for more than&#xD;
             3 minutes,&#xD;
&#xD;
               -  Low blood pressure (systolic blood pressure &lt;90 mmHg, diastolic blood pressure&#xD;
                  &lt;50 mmHg)&#xD;
&#xD;
               -  High blood pressure (systolic blood pressure greater than 150 mmHg, diastolic&#xD;
                  blood pressure greater than 100 mmHg)&#xD;
&#xD;
          -  Test subjects who are deemed unsuitable for participating in clinical trials due to&#xD;
             clinical laboratory tests, ECG results, or other reasons&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsang Yu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <results_first_submitted>March 19, 2020</results_first_submitted>
  <results_first_submitted_qc>September 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03492398/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A HY209 Placebo</title>
          <description>single dose of placebo&#xD;
total 8 subjects participated.</description>
        </group>
        <group group_id="P2">
          <title>Cohort A HY209 0.05% Gel</title>
          <description>single dose of HY209 0.05% gel&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P3">
          <title>Cohort A HY209 0.1% Gel</title>
          <description>single dose of HY209 0.1% gel&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P4">
          <title>Cohort A HY209 0.3% Gel</title>
          <description>single dose of HY209 0.3% gel&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P5">
          <title>Cohort A HY209 0.5% Gel</title>
          <description>single dose of HY209 0.5% gel&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P6">
          <title>Cohort B Placebo</title>
          <description>multiple dose of placebo&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P7">
          <title>Cohort B HY209 0.1% Gel</title>
          <description>multiple dose of HY209 0.1% gel&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P8">
          <title>Cohort B HY209 0.3% Gel</title>
          <description>multiple dose of HY209 0.3% gel&#xD;
total 6 subjects participated.</description>
        </group>
        <group group_id="P9">
          <title>Cohort B HY209 0.5% Gel</title>
          <description>multiple dose of HY209 0.5% gel&#xD;
total 6 subjects participated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A Placebo</title>
          <description>single dose of placebo 8 subjects</description>
        </group>
        <group group_id="B2">
          <title>Cohort A HY209 0.05% Gel</title>
          <description>single dose of HY209 0.05% gel 6 subjects</description>
        </group>
        <group group_id="B3">
          <title>Cohort A HY209 0.1% Gel</title>
          <description>single dose of HY209 0.1% gel 6 subjects</description>
        </group>
        <group group_id="B4">
          <title>Cohort A HY209 0.3% Gel</title>
          <description>single dose of HY209 0.3% gel 6 subjects</description>
        </group>
        <group group_id="B5">
          <title>Cohort A HY209 0.5% Gel</title>
          <description>single dose of HY209 0.5% gel 6 subjects</description>
        </group>
        <group group_id="B6">
          <title>Cohort B Placebo</title>
          <description>multiple dose of placebo 6 subjects</description>
        </group>
        <group group_id="B7">
          <title>Cohort B HY209 0.1% Gel</title>
          <description>multiple dose of HY209 0.1% gel 6 subjects</description>
        </group>
        <group group_id="B8">
          <title>Cohort B HY209 0.3% Gel</title>
          <description>multiple dose of HY209 0.3% gel 6 subjects</description>
        </group>
        <group group_id="B9">
          <title>Cohort B HY209 0.5% Gel</title>
          <description>multiple dose of HY209 0.5% gel 6 subjects</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="6"/>
                    <count group_id="B9" value="6"/>
                    <count group_id="B10" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment Emergent Adverse Events</title>
        <description>Number of participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
        <time_frame>upto Day 8(single dosing), upto Day 38(multiple dosing)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Placebo</title>
            <description>single dose of placebo&#xD;
total 8 subjects assigned.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A HY209 0.05% Gel</title>
            <description>single dose of HY209 0.05% gel&#xD;
total 6 subjects assigned.</description>
          </group>
          <group group_id="O3">
            <title>Cohort A HY209 0.1% Gel</title>
            <description>single dose of HY209 0.1% gel&#xD;
total 6 subjects assigned.</description>
          </group>
          <group group_id="O4">
            <title>Cohort A HY209 0.3% Gel</title>
            <description>single dose of HY209 0.3% gel&#xD;
total 6 subjects assigned.</description>
          </group>
          <group group_id="O5">
            <title>Cohort A HY209 0.5% Gel</title>
            <description>single dose of HY209 0.5% gel&#xD;
total 6 subjects assinged.</description>
          </group>
          <group group_id="O6">
            <title>Cohort B Placebo</title>
            <description>multiple dose of placebo&#xD;
total 6 subjects assigned.</description>
          </group>
          <group group_id="O7">
            <title>Cohort B HY209 0.1% Gel</title>
            <description>multiple dose of HY209 0.1% gel&#xD;
total 6 subjects assigned.</description>
          </group>
          <group group_id="O8">
            <title>Cohort B HY209 0.3% Gel</title>
            <description>multiple dose of HY209 0.3% gel&#xD;
total 6 subjects assigned.</description>
          </group>
          <group group_id="O9">
            <title>Cohort B HY209 0.5% Gel</title>
            <description>multiple dose of HY209 0.5% gel&#xD;
total 6 subjects assigned.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment Emergent Adverse Events</title>
          <description>Number of participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>upto Day 8(single dosing), upto Day 38(multiple dosing)</time_frame>
      <desc>Number of participants with abnormal laboratory values and/or adverse events that are related to treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A HY209 Placebo</title>
          <description>single dose of placebo&#xD;
total 8 subjects assigned.</description>
        </group>
        <group group_id="E2">
          <title>Cohort A HY209 0.05% Gel</title>
          <description>single dose of HY209 0.05% gel&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E3">
          <title>Cohort A HY209 0.1% Gel</title>
          <description>single dose of HY209 0.1% gel&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E4">
          <title>Cohort A HY209 0.3% Gel</title>
          <description>single dose of HY209 0.3% gel&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E5">
          <title>Cohort A HY209 0.5% Gel</title>
          <description>single dose of HY209 0.5% gel&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E6">
          <title>Cohort B Placebo</title>
          <description>multiple dose of placebo&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E7">
          <title>Cohort B HY209 0.1% Gel</title>
          <description>multiple dose of HY209 0.1% gel&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E8">
          <title>Cohort B HY209 0.3% Gel</title>
          <description>multiple dose of HY209 0.3%&#xD;
total 6 subjects assigned.</description>
        </group>
        <group group_id="E9">
          <title>Cohort B HY209 0.5% Gel</title>
          <description>multiple dose of HY209 0.5%&#xD;
total 6 subjects assigned.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Appication site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Inseung Jeon</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>82-2-2072-1920</phone>
      <email>isjeon0127@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

